Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Infection and Drug Resistance|June 20, 2019
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA projectPaola Bagella, Nicola Squillace, Elena Ricci, et al.
Brain : a Journal of Neurology|August 22, 2024
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized studyAndrea Calcagno, Jessica Cusato, Paola Cinque, et al.
HIV Research & Clinical Practice|February 4, 2026
QuantiFERON-TB gold plus in people living with HIV: independence from CD4+ T-cell counts in a low TB-burden settingErika Asperges, Roberto Gulminetti, Laura Maiocchi, et al.
BMC Infectious Diseases|August 2, 2018
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)Lucia Taramasso, Paola Tatarelli, Elena Ricci, et al.
Antiviral Therapy|March 4, 2014
OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patientsGiampiero Carosi, Raffaele Bruno, Giuseppe Cariti, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2025
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study)Diego Ripamonti, Laura Comi, Andrea Francavilla, et al.
AIDS (London, England)|March 15, 2019
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapyAntonella Castagna, Stefano Rusconi, Roberto Gulminetti, et al.
Viruses|November 11, 2022
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort StudyLucia Taramasso, Antonio Falletta, Elena Ricci, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 1, 2020
Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?Andrea Lombardi, Marta Colaneri, Kesav Aditya Vijayagopal, et al.
Viruses|September 27, 2025
Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO RegistryFilippo Lagi, Michele Bellomo, Riccardo Lolatto, et al.
Pageof 5